Generic Clindesse Availability
CLINDESSE (clindamycin phosphate - cream;vaginal)
Manufacturer: KV PHARM
Approval date: November 30, 2004
Strength(s): EQ 2% BASE [RLD]
Has a generic version of Clindesse been approved?
No. There is currently no therapeutically equivalent version of Clindesse available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Clindesse. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Pharmaceutical preparations and methods for their administration
Issued: November 30, 1999
Inventor(s): Ragavan; Vanaja V. & DiPiano; Gerrianne M.
Formulations which have been developed for topical or local delivery intrapelvically, intraperitoneally or directly on reproductive organs of interest administration to a region such as the female reproductive system, provide for increased comfort, increased bioavailability, rapid and relatively high blood levels in the regions to be treated in the substantial absence of systemic levels of drug which might cause side effects. These formulations consist of drug micro or nanoparticles, which may be formed of drug alone or in combination with an excipient or polymeric carrier. The excipient or polymer may be used to manipulate release rates and to increase adhesion to the affected region. The particulate formulation can be applied as a dried powder, a liquid suspension or dispersion, or as a topical ointment, creme, lotion, foam or suppository.Patent expiration dates:
- November 17, 2017✓✓
- November 17, 2017
Bioadhesive drug delivery system
Issued: May 31, 2005
Inventor(s): Kirschner; Mitchell I. & Levinson; R. Saul & Riley; Thomas C. & Hermelin; Marc S.
Assignee(s): KV Pharmaceutical Company
The present invention relates to a novel essentially pH neutral vaginal drug delivery system suitable for modified delivery of a therapeutically active material in the vaginal cavity. The vaginal drug delivery system comprises an essentially pH neutral emulsion having globules having two phases, an internal water soluble phase and an external water-insoluble phase or film, wherein the water-soluble interior phase contains a therapeutically active drug or drugs. One novel aspect of the vaginal drug delivery system is that the internal water soluble phase comprises an acidic buffered phase.Patent expiration dates:
- April 27, 2023✓✓
- April 27, 2023
- Clindesse Consumer Information (Drugs.com)
- Clindesse cream Consumer Information (Wolters Kluwer)
- Clindesse Advanced Consumer Information (Micromedex®)
- Clindamycin cream Consumer Information (Wolters Kluwer)
- Clindamycin foam Consumer Information (Wolters Kluwer)
- Clindamycin gel Consumer Information (Wolters Kluwer)
- Clindamycin lotion Consumer Information (Wolters Kluwer)
- Clindamycin solution Consumer Information (Wolters Kluwer)
- Clindamycin suppositories Consumer Information (Wolters Kluwer)
- Clindamycin swab Consumer Information (Wolters Kluwer)
- Clindamycin topical Consumer Information (Cerner Multum)
- Clindamycin vaginal Consumer Information (Cerner Multum)
- Clindacin ETZ Topical Advanced Consumer Information (Micromedex®)
- Z-Clinz Topical Advanced Consumer Information (Micromedex®)
- Clindamycin Topical Advanced Consumer Information (Micromedex®)
- Clindamycin Vaginal Advanced Consumer Information (Micromedex®)
- Clindamycin Phosphate topical AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|